Instituto Bioclon
http://dbpedia.org/resource/Instituto_Bioclon an entity of type: Thing
The Instituto Bioclon S.A. de C.V. (Bioclon Institute) was formed in 1990 to research and develop F(ab’)2 antivenoms. On May 6, 2015 they received approval from the FDA to commercialize ANAVIP becoming their second drug approved by the FDA after ANASCORP. Both are commercialized in the US by Rare Disease Therapeutics, Inc. The company is performing clinical trials to get approval for a third drug, ANALATRO, designed to treat black widow spider envenomation.
rdf:langString
rdf:langString
Instituto Bioclon
rdf:langString
Instituto Bioclon S.A. de C.V.
rdf:langString
Instituto Bioclon S.A. de C.V.
xsd:integer
31926273
xsd:integer
1061345181
xsd:integer
1990
rdf:langString
Silanes Laboratories
rdf:langString
Antivenom research and development
rdf:langString
Private
rdf:langString
The Instituto Bioclon S.A. de C.V. (Bioclon Institute) was formed in 1990 to research and develop F(ab’)2 antivenoms. On May 6, 2015 they received approval from the FDA to commercialize ANAVIP becoming their second drug approved by the FDA after ANASCORP. Both are commercialized in the US by Rare Disease Therapeutics, Inc. The company is performing clinical trials to get approval for a third drug, ANALATRO, designed to treat black widow spider envenomation.
xsd:nonNegativeInteger
3819
xsd:gYear
1990